We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $824M
1-Year Est. Return 78.19%
This Fund
S&P 500
This Quarter Est. Return
+6.29%
1 Year Est. Return
+78.19%
3 Year Est. Return
+156.18%
5 Year Est. Return
+168.38%
10 Year Est. Return
+388.18%
AUM
$550M
AUM Growth
+$21.3M
Cap. Flow
-$7.01M
Cap. Flow %
-1.27%
Top 10 Hldgs %
36.64%
Holding
133
New
19
Increased
31
Reduced
55
Closed
4

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$10.1M
2
PG icon
Procter & Gamble
PG
+$6.58M
3
ADM icon
Archer Daniels Midland
ADM
+$5.96M
4
ABT icon
Abbott
ABT
+$3.08M
5
AZTA icon
Azenta
AZTA
+$2.52M

Sector Composition

Rank Sector Weight
1 Healthcare 24.11%
2 Industrials 21.96%
3 Technology 19.46%
4 Energy 10.77%
5 Utilities 9.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
XOM icon
1
ExxonMobil
XOM
$644B
$34.5M 6.28%
406,019
+289
+0.1% +$23.6K
EMR icon
2
Emerson Electric
EMR
$86.6B
$32.4M 5.9%
423,441
+5,105
+1% +$377K
GLW icon
3
Corning
GLW
$128B
$23.6M 4.28%
667,590
-47,600
-7% -$1.55M
PFE icon
4
Pfizer
PFE
$159B
$19.8M 3.6%
473,083
+173
+0% +$6.66K
MRK icon
5
Merck
MRK
$366B
$17.8M 3.23%
262,485
-1,153
-0.4% -$73.5K
SLB icon
6
SLB Ltd
SLB
$85.1B
$17.4M 3.16%
284,928
+3,014
+1% +$194K
INTC icon
7
Intel
INTC
$473B
$15.1M 2.74%
318,278
-5,250
-2% -$255K
NVS icon
8
Novartis
NVS
$292B
$14M 2.55%
181,359
-234
-0.1% -$17.3K
JNJ icon
9
Johnson & Johnson
JNJ
$646B
$13.9M 2.53%
100,597
-76,112
-43% -$10.1M
ABT icon
10
Abbott
ABT
$195B
$13.1M 2.39%
179,214
-46,916
-21% -$3.08M
IBM icon
11
IBM
IBM
$222B
$12.8M 2.33%
88,533
-2,302
-3% -$322K
GVA icon
12
Granite Construction
GVA
$5.44B
$12.2M 2.22%
267,009
+74,324
+39% +$3.63M
LNN icon
13
Lindsay Corp
LNN
$1.16B
$11.7M 2.13%
116,998
-642
-0.5% -$60.3K
MSFT icon
14
Microsoft
MSFT
$3.81T
$11.5M 2.09%
100,462
-875
-0.9% -$94.9K
OGE icon
15
OGE Energy
OGE
$9.45B
$10.8M 1.97%
297,633
-1,748
-0.6% -$63.6K
BMY icon
16
Bristol-Myers Squibb
BMY
$136B
$10.4M 1.89%
167,140
-1,835
-1% -$109K
FLS icon
17
Flowserve
FLS
$10.2B
$10.1M 1.84%
185,435
-579
-0.3% -$28K
TT icon
18
Trane Technologies
TT
$98.8B
$9.73M 1.77%
95,153
-1,740
-2% -$170K
BCE icon
19
BCE
BCE
$21.9B
$9.68M 1.76%
238,845
+5,709
+2% +$235K
MDU icon
20
MDU Resources
MDU
$4.16B
$9.01M 1.64%
922,382
+22,065
+2% +$236K
EVRG icon
21
Evergy
EVRG
$18.6B
$8.99M 1.63%
163,735
-1,839
-1% -$104K
WTS icon
22
Watts Water Technologies
WTS
$12.2B
$8.95M 1.63%
107,858
-870
-0.8% -$72K
CIEN icon
23
Ciena
CIEN
$53.6B
$8.59M 1.56%
275,000
+19,034
+7% +$533K
EEMV icon
24
iShares MSCI Emerging Markets Min Vol Factor ETF
EEMV
$3.65B
$8.34M 1.52%
140,581
+13,050
+10% +$765K
HON icon
25
Honeywell
HON
$68.9B
$8.32M 1.51%
55,374
-5,312
-9% -$753K

Similar funds

John G. Ullman & Associates's Q3 2018 Portfolio in Review

As of Q3 2018, John G. Ullman & Associates held 133 positions worth $550M, up 4% from $529M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

John G. Ullman & Associates's Q3 2018 filing shows 19 new, 31 increased, 55 reduced and 4 closed positions. Its largest new stake was Dentsply Sirona: 141,500 shares worth $5.34M. The largest sale was Johnson & Johnson, an estimated $10.1M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 24% a quarter earlier, followed by Industrials and Technology.

  • John G. Ullman & Associates's largest Q3 2018 buy was Dentsply Sirona: 141,500 shares worth $5.34M.
  • John G. Ullman & Associates added most to Granite Construction in Q3 2018, an estimated $3.63M increase.
  • John G. Ullman & Associates's biggest Q3 2018 reduction was Johnson & Johnson, cutting an estimated $10.1M.
  • John G. Ullman & Associates fully exited Procter & Gamble in Q3 2018, selling an estimated $6.58M.
  • John G. Ullman & Associates's ten largest holdings make up 37% of its $550M portfolio in Q3 2018.
  • John G. Ullman & Associates opened 19 new positions and closed 4 in Q3 2018.
  • John G. Ullman & Associates's portfolio value rose 4% quarter-over-quarter to $550M.

Based on John G. Ullman & Associates's 13F filing for Q3 2018, filed 2 Nov 2018.